Friday, July 12, 2013 10:10:26 AM
Major NY Research Firm Sees SVFC as Best in Play for Stem Cell Treatment
Last Updated: July 08, 2013 - 9:00am EST
(NEW YORK)--Intellicell Biosciences, Inc. (OTC:SVFC), a developer of technology for the extraction of autologous stem cells for physicians in the area of
regenerative medicine, was was mentioned in stem cell sector research report issued out today by New York based Maxim Group.
In the report on the sector, Maxim Group's analyst commented, "The company has treated over 300 patients and in some cases with dramatic results. We went
so far as to review patients stories and case histories, publications and even met with the company’s attorneys (ex-FDA reviewers) to understand the
definitions of minimally manipulated and the legal guidelines by which the company’s process allows physicians to treat patients. We left believing that this
is the only company, at the moment that qualifies with a process that meets current guidelines.”
This is a major development as this highlights SVFC as one of the only stem cell companies in the United States cleared to treat patients.
Maxim Group is a large New York institutional brokerage firm with an impressive research and investment banking division. www.maximgrp.com
In addition, Ludlow Research, a small cap equity research firm had also issued a research opinion on SVFC regarding their treatment using stem cells. All this
news, and their recent US patent as sent the stock to the most active trading list.
Ludlow Research Highlights
- Unique Stem Cell Extraction Technology from Blood Vessels
- FDA Registered Facility in NYC
- One of few cGTP Cell Manufacturing Facilities in US
- Use of Ultrasonic Cavitation instead of Enzymes
- Patent for Stem Cell Extraction Process
- Appointment of Dr Zain Khalpey to Advisory Board
FDA Compliant Stem Cell Facility
In November 2012, the Company was notified according to the Federal Drug Administration (“FDA”) validation registration number 3009842420, that its new
facility located at 460 Park Avenue, New York, NY 10022 is now registered to recover, process, package, store, and label human cells and tissue products
(HCT/P’s), such as the IntelliCell autologous stromal vascular fraction cellular product.
IntelliCell's proprietary patented method for deriving blood vessel originated vascular cells from adipose (fat) tissue by use of ultrasonic cavitation. This
technology is an innovative mechanical method for the separation of stromal vascular fraction without the use of enzymes. Ultrasonic cavitation is an
innovative mechanical method of separating SVFCs from fat tissue. Vascular cells derived by IntelliCell's proprietary method are potentially useful in
bringing the promise of regenerative medicine to many therapeutic and aesthetic procedures.
Open House Tour Event
Very rarely do we get the chance to tour a companies operation facilities. Since based in midtown Manhattan we had the chance to tour SVFC medical treatment
facilities, and can say first hand that their facilities were very impressive. Not only were their people visiting for basic cosmetic treatments, which the
company uses to generate revenue and offset operational costs, but the back-side treatment facilities were quit large and impressive. There were a number of
completed clean and professional minimal surgical treatment rooms, offices, and very impressive and FDA compliant stem cell extraction processing room, which
was managed by very experienced and professional personal.
The Company is working on conducting an open house event where shareholders, and institutional investors will be invited to tour their facilities on Park
Avenue, and meet the executives from IntelliCell. An announcement of this upcoming open house could be released in the coming days, and to potentially attend
this event in NYC you can register here to request more information.
All in all, SVFC isn't one of your regular penny stock, or run of the mill R&D stem cell stocks. SVFC has a very impressive treatment facility that will not
only manufacture stem cells through their now patented process, but treat patients as well. This places SVFC as one of the very few stem cell treatment and
manufacturers in the US, and they are always open to provide guided tours if you ever find yourself in New York City. This is defiantly one to watch.
Last Updated: July 08, 2013 - 9:00am EST
(NEW YORK)--Intellicell Biosciences, Inc. (OTC:SVFC), a developer of technology for the extraction of autologous stem cells for physicians in the area of
regenerative medicine, was was mentioned in stem cell sector research report issued out today by New York based Maxim Group.
In the report on the sector, Maxim Group's analyst commented, "The company has treated over 300 patients and in some cases with dramatic results. We went
so far as to review patients stories and case histories, publications and even met with the company’s attorneys (ex-FDA reviewers) to understand the
definitions of minimally manipulated and the legal guidelines by which the company’s process allows physicians to treat patients. We left believing that this
is the only company, at the moment that qualifies with a process that meets current guidelines.”
This is a major development as this highlights SVFC as one of the only stem cell companies in the United States cleared to treat patients.
Maxim Group is a large New York institutional brokerage firm with an impressive research and investment banking division. www.maximgrp.com
In addition, Ludlow Research, a small cap equity research firm had also issued a research opinion on SVFC regarding their treatment using stem cells. All this
news, and their recent US patent as sent the stock to the most active trading list.
Ludlow Research Highlights
- Unique Stem Cell Extraction Technology from Blood Vessels
- FDA Registered Facility in NYC
- One of few cGTP Cell Manufacturing Facilities in US
- Use of Ultrasonic Cavitation instead of Enzymes
- Patent for Stem Cell Extraction Process
- Appointment of Dr Zain Khalpey to Advisory Board
FDA Compliant Stem Cell Facility
In November 2012, the Company was notified according to the Federal Drug Administration (“FDA”) validation registration number 3009842420, that its new
facility located at 460 Park Avenue, New York, NY 10022 is now registered to recover, process, package, store, and label human cells and tissue products
(HCT/P’s), such as the IntelliCell autologous stromal vascular fraction cellular product.
IntelliCell's proprietary patented method for deriving blood vessel originated vascular cells from adipose (fat) tissue by use of ultrasonic cavitation. This
technology is an innovative mechanical method for the separation of stromal vascular fraction without the use of enzymes. Ultrasonic cavitation is an
innovative mechanical method of separating SVFCs from fat tissue. Vascular cells derived by IntelliCell's proprietary method are potentially useful in
bringing the promise of regenerative medicine to many therapeutic and aesthetic procedures.
Open House Tour Event
Very rarely do we get the chance to tour a companies operation facilities. Since based in midtown Manhattan we had the chance to tour SVFC medical treatment
facilities, and can say first hand that their facilities were very impressive. Not only were their people visiting for basic cosmetic treatments, which the
company uses to generate revenue and offset operational costs, but the back-side treatment facilities were quit large and impressive. There were a number of
completed clean and professional minimal surgical treatment rooms, offices, and very impressive and FDA compliant stem cell extraction processing room, which
was managed by very experienced and professional personal.
The Company is working on conducting an open house event where shareholders, and institutional investors will be invited to tour their facilities on Park
Avenue, and meet the executives from IntelliCell. An announcement of this upcoming open house could be released in the coming days, and to potentially attend
this event in NYC you can register here to request more information.
All in all, SVFC isn't one of your regular penny stock, or run of the mill R&D stem cell stocks. SVFC has a very impressive treatment facility that will not
only manufacture stem cells through their now patented process, but treat patients as well. This places SVFC as one of the very few stem cell treatment and
manufacturers in the US, and they are always open to provide guided tours if you ever find yourself in New York City. This is defiantly one to watch.
That gibberish above is MY own opinion. Go get your own!
Visit LOA! Chart Traders:
http://investorshub.advfn.com/boards/board.aspx?board_id=12543
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.